Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) attributable profit rose 25% to 764.8 million yuan in the first quarter from 609.7 million yuan in the year-ago period, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share at the drug company increased 26% to 0.29 yuan from 0.23 yuanin the year-ago period.
Operating income declined 7.3% to 9.42 billion yuan from 10.2 billion yuan in the prior-year period.
Shares slipped 4% in Hong Kong during afternoon trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.